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Introduction. We aim to describe the time of entry into care and factors associated with being lost to program (LTP) in pregnant
women on Option B Plus in an integrated HIV and antenatal care (ANC) clinic in Uganda. Methods. We included all pregnant
women enrolled into the integrated HIV-ANC clinic from January 2012 to 31st July 2014, while the follow up period extended up
to October 30th 2015. LTP was defined as being out of care for ≥3 months. Results. Overall 856 women were included. Only 36.4%
(86/236) of the women were enrolled in the first trimester. Overall 69 (8.1%) were LTP. In the multivariate analysis older women
(HR: 0.80 per five-year increase, CI: 0.64–1.0, and 𝑃 = 0.060) and women on ART at the time of pregnancy (0.58, CI: 0.34–0.98,
and 𝑃 = 0.040) were more likely not to be LTP. Among women already on ART at the time of pregnancy no factor was associated
with LTP. Conclusion. Our results suggest the need for interventions to enhance prompt linkage of HIV positive women to HIV
services for ART initiation and for increased retention particularly in young and ART naive women.
1. Background
In many developed countries, paediatric HIV has been
virtually eliminated [1]. The United Nations programme
on HIV/AIDS (UNAIDS) estimates that currently 330,000
children are infected with HIV/AIDS worldwide, 90% of
whom are living in Sub-Saharan Africa [2, 3]. Mother-to-
child transmission (MTCT) is the primary mode of HIV
infection in children either during pregnancy, labor, and
delivery or through breast feeding [4–6]. Several studies have
proven that antiretroviral drugs decrease HIV transmission
from the mother to the baby [7–11]. Particularly, the use
of triple antiretroviral (ART) therapy during pregnancy has
been proven to be highly effective in reducing mother-
to-child HIV transmission from 15% up to 45% with no
treatment at all to below 5% [12].
To attain virtual elimination of paediatric HIV, programs
in resource limited settings have scaled up integrated preven-
tion of mother-to-child transmission (PMTCT) programs to
identify and enroll HIV infected pregnant women into care
and treatment services [13–16].
Since 2012, the WHO recommends immediate start of
lifelong ART constituted by tenofovir, emtricitabine, and efa-
virenz, for all HIV positive pregnant and breast feeding
women presenting into care regardless of their CD4 count or
WHO clinical staging; this strategy is also known as Option
B Plus [17].
Despite programs’ efforts to scale up Option B Plus
strategy by 50% coverage [18] and with up to 68.1% women
starting ART during antenatal care and after delivery in Sub-
Saharan Africa, the effectiveness of this prevention strategy
to move towards an HIV free generation [19] is undermined
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by high rates of being lost to program (LTP) [20].The rates of
LTP are particularly alarming in the postpartum period (up
to 50%) [21, 22].
So far most of the national programs in Sub-Saharan
Africa, while challengedwith low retention in care ofmothers
and their infants, are limited with interventions to improve
retention into care and reduce LTP [23].
In Uganda, routine HIV screening is recommended for
all women presenting for antenatal or delivery care in all
public health facilities [24]; women who test HIV positive are
offered, in addition to antenatal care (ANC), Option B Plus
during prenatal and postnatal visits up to 18 months after
delivering and are thereafter referred to HIV care services.
However an earlier evaluation frompublic clinics inKampala,
the capital city, revealed alarming rates of being lost to follow-
up between 25% and 58.8% [25].
At the Infectious Diseases Institute (IDI), Kampala,
Uganda, an HIV centre of excellence, in order to increase
retention into care and to avoid referrals to and from ANC
services, with potential loss from care, an integrated HIV-
ANC clinic was implemented in 2012. The main objective of
this study was to describe the time of entry into care into the
integrated HIV-ANC clinic and investigate factors associated
with being lost to program.
2. Methods
2.1. Study Setting and Population. The Infectious Diseases
Institute (IDI), Makerere University, is an HIV centre of
excellence [26] located in Mulago Teaching Hospital in
Kampala with over 8,000 HIV positive individuals receiving
care. The IDI clinic began providing HIV care in 2002, while
free antiretroviral treatment has been provided since April
2004. In 2012 an integrated HIV-ANC clinic was put into
service, where all pregnant women receive antenatal andHIV
care including Option B Plus.
2.2. The Integrated HIV-ANC Clinic. Women suspected to be
pregnant on the basis of the date of their lastmenstrual period
receive a targeted pregnancy confirmatory test, and if found
positive they are referred to the integrated HIV-ANC clinic,
while new HIV positive pregnant or breast feeding women
referred to IDI are directed to the HIV-ANC clinic immedi-
ately at enrolment into care. In this clinic, pregnant women
are offered iron and folic acid supplementation, antiretro-
viral drugs, prevention and management of opportunistic
infections, education on obstetric practices, especially during
labor and delivery, and counseling on infant feeding options.
Mothers already on ART and those ART naive are prepared
to start or switch to tenofovir, emtricitabine, and efavirenz
as part of Option B Plus. At the time of this analysis ART
was monitored using CD4 counts; viral load testing was not
routinely available.
The clinic is staffed by a trained team of 3medical officers,
2 nurses, and a nurse-counselor; it is supervised by a senior
medical officer and assisted in logistic and health education
tasks by a peer supporter.
2.3. Data Collection. At IDI patients’ clinical information
is captured into an in-house built provider-based electronic
medical record EMR system called Integrated Clinic Enter-
prise Application (ICEA) [27]. The system generates auto-
mated queries to eliminate omission of mandatory fields and
has internal consistency checks which ensure that the data
entered is accurate. Within the main patient’s management
application, information on pregnantwomen and their babies
can be entered in a dedicated module.
The Option B Plus ICEA module captures data before
and after delivery which include information on whether the
pregnancy was intended, gravity, parity, number of abortions,
last normal menstrual period, expected date of delivery, and
birth outcomes.
2.4. Statistical Analysis. In this analysis, we included all preg-
nant women who started ART in the HIV-ANC integrated
clinic from 1st January 2012, the year Option B Plus was
implemented, to 31st July 2014, while the follow-up period
extended up to 30th October 2015. We used proportion
to describe the point of entry into care (1st, 2nd, and 3rd
trimester, on the day of delivery and postpartum) and the
magnitude and reason of discontinuation from care (LTP,
death, or transferred to another program). We used Kaplan-
Meier survival analysis to estimate time to LTP. Awomanwas
defined as LTP if she was alive but had not come back for
her appointment for at least 3 months; women who had been
transferred out of care but were attending another facility and
receiving ART were not considered LTP.
Women were followed up from time of enrolment into
the ANC to date of last clinic encounter or date of database
closure for those still in care. We used Cox proportional
hazards model methods to identify factors associated with
LTP among women enrolled into the integrated HIV-ANC.
Variables included in the model were age, WHO stage,
parity, CD4 count, and ART status (ART naive versus on
ART). Variables with a 𝑃 value ≤0.25 in the unadjusted Cox
proportional hazards model and those of clinical significance
were included in the multivariate model. We also conducted
a subanalysis including women already on ART at the time of
pregnancy.
Analysis was performed using STATA 12.2, Texas, USA.
2.5. Ethical Statement. This study was approved and annually
renewed by the School of Medicine Research and Ethics
Committee, Makerere University Medical School (Reference
number 2009-120), and the Uganda National Council for
Science and Technology.The investigators obtained verbal or
written consent waiver; all the information is analysed after
stripping it of unique personal identifiers.
3. Results
Overall 856 pregnant women were included in the analysis;
at the time of the enrolment into the HIV-ANC integrated
clinic, the median age was 31 years (IQR: 26–35), and 302
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Figure 1: Showing point of entry and being lost to program by gestational age.
(35.3%) were in WHO stage 3/4; the median CD4 count was
433 cells/𝜇L (IQR: 301–638), 236 (27.6%)wereARTnaive, and
329 (39.5%) had already had at least 2 pregnancies (Table 1).
Figure 1 shows the time of entry into care in the integrated
HIV-ANC clinic by gestational age and numbers of patients
LTP. Only 32.2% (86/276) of the women were enrolled in the
first trimester, and of these 86 (31.2%) were ART naive.Three
hundred and sixty-three women (42.1%) were enrolled in the
2nd trimester, and of these 99 (27.3%) were ART naive; only
17 (2%) of patients were enrolled after birth, and among these
4 (23.5%) were ART naive.
The overall proportion of women LTP was 8.1% (69/856)
with higher proportion of LTP observed in the postdelivery
period (Figure 1).
There was a total follow-up time of 22262 personmonths.
The median time to loss to follow-up was 12.4 (4.2–21.3)
months and active patients had a follow-up time of 28.8
(20.7–37.5) months.
Figure 2 shows the cumulative probability of being LTFU
by ART status; women who were ART naive at the time of
pregnancy had a higher cumulative probability (0.155, 95%
CI: 0.102–0.232) of being LTFU as compared to those already
on ART (0.085, 95% CI: 0.0587–0.123) (𝑃 = 0.025).
In the univariate analysis older age (HR: 0.77, CI:
0.62–0.96, and 𝑃 = 0.019) being on ART at the time of
pregnancy (HR: 0.56, CI: 0.33–0.94, and 𝑃 = 0.0270) was
associated with lower risk of being lost to program (Table 2).
In themultivariate analysis women of older age (HR: 0.80
per five-year increase, CI: 0.64–1.0, and 𝑃 = 0.060) and
women onART at the time of pregnancy (0.58, CI: 0.34–0.98,
and 𝑃 = 0.040) remained factors associated with reduced
LTFU. In the subanalysis that included only womenwhowere
not ART naive at the time of pregnancy, we found no factors
associated significantly with LTP.
Table 1: Characteristic of pregnant women at enrollment in the
integrated HIV-antenatal clinic.
Characteristics 𝑁 = 856
Age (years), median (IQR) 31 (26–35)
Stage of pregnancy, 𝑛 (%)
First trimester 276 (32.2)
Second trimester 363 (42.4)
Third trimester 194 (22.7)
On delivery 6 (0.7)
After birth 17 (2.0)
Already on ART, 𝑛 (%) 620 (72.4)
WHO clinical stage 3/4, 𝑛 (%) 302 (35.3)
Parity >2,𝑁 (%) 329 (39.5)
CD4 cells/𝜇L, median (IQR) 433 (301–638)
𝑛 (%) ≤350 288 (33.7)
351–500 219 (25.6)
>500 347 (40.6)
ART: antiretroviral treatment.
4. Discussion
In this study we described the point of entry and being lost
to program in an integrated HIV-ANC clinic in Kampala,
Uganda.We found that in our program rates of LTP are lower,
as compared to other programs in in Sub-Saharan Africa;
findings from Ethiopia demonstrated 16.5% [28] and Malawi
17% [29] of women LTP. Our results suggest that training
dedicated staff and integration of services may lead to good
levels of retention into care.
However in our program, similarly to what is reported
from other countries [30, 31] despite overall good retention,
only one third of ART naive women joined in the first
trimester, with potential risk of transmission to their infants.
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Table 2: Factors associated with loss to program using Cox Proportional Hazards model.
Characteristics Unadjusted HR (95% CI) 𝑃 value Adjusted HR (95% CI) 𝑃 value
Age per 5 year increase 0.77 (0.62–0.96) 0.019 0.80 (0.64–1.00) 0.060
Gestational age
First trimester 1.00
Second trimester 0.75 (0.40−1.41) 0.370 0.78 (0.42–1.46) 0.439
Third trimester 1.44 (0.77–2.69) 0.260 1.52 (0.80–2.82) 0.210
On delivery 3.45 (0.46–25.81) 0.230 4.22 (0.56–31.9) 0.163
After birth 2.00 (0.47–8.58) 0.350 2.20 (0.51–9.42) 0.290
ART status at enrollment
ART naive 1.00
On ART 0.56 (0.33–0.94) 0.027 0.58 (0.34–0.98) 0.040
WHO clinical stage
I-II 1.00
III-IV 0.91 (0.54–1.54) 0.730
Parity
≤2 1.00
>2 0.82 (0.48–1.39) 0.454
CD4 cells/𝜇L
≤350 1.00
350–500 0.98 (0.51–1.92) 0.980
>500 0.97 (0.54–1.73) 0.910
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Figure 2: Showing cumulative probability of being lost to program
by ART status.
In our study we found higher rates of LTP in younger
women and in women who were ART naive at the time
of pregnancy and in the postpartum period. The high rates
of LTP among young women are likely to reflect the low
retention into the cascade from testing HIV positive to being
uninterruptedly on treatment observed in this group [32].
Several factors may contribute to this; for example, young
people are less concerned about their health compared to
older people, they tend to have more risky lifestyle due
to a youthful sense of invulnerability, and they are usually
healthier and often engage into activities that interfere with
routine clinic scheduled visits [33–35]. Additionally, stigma
related to pregnancy among young people can influence
retention in care [36, 37].
We also found that women on ART at the time of
pregnancy were less likely to be LTP. Our findings are
consistent with those of previous studies which indicated that
ART experienced patients are more likely to be retained in
care [28].
We observed that LTP was higher during postpartum
period. Similar findings were reported in a cohort study done
in SouthAfrica in which 49% of women had disengaged from
care postpartum [21]. These findings are also consistent with
results from other studies [21, 38, 39]. We can hypothesize
that, with the decentralization of HIV services in including
provision of antiretroviral drugs, a proportion of women self-
transfer to facilities nearer to their home after delivery [40].
This is possible in order to reduce transport costs.
Lack of disclosure of HIV positive status has been
associated with increased LTFU [23, 41] in women enrolled
in PMTCT programs. We hypothesize that women who have
not disclosed report to their partners that they visit monthly
a health care facility for ANC, but not for HIV care; after
delivering they may stop coming to the clinic since they
cannot justify to their partners’ monthly visits to a health care
facility.
One limitation of this study was that the information
was obtained from routinely collected data, which may pose
challenges in terms of data quality. However a previous
evaluation of our database showed high completeness and
consistency of data [27]. Another limitation is that we did not
have preintegratedHIV-ANC clinic data for comparison pur-
poses, and therefore we cannot attribute the high retention
demonstrated in this study entirely to HIV-ANC integrated
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clinic, as other measures have been implemented at the entire
clinic level to improve retention in for all patients.
Although reports from observation studies in Sub-
Saharan Africa seem to suggest that integration of ANC
including Option B+ and HIV services improves retention,
this needs to be validated in more rigorous studies [42].
5. Conclusion
While in our program we achieved good retention of preg-
nant women enrolled in the Option B+ program, integration
of services may not be sufficient to reduce being lost to
program among young women and those who are naive.
Where available, for groups at risk of being lost to program,
resources should be utilized for other interventions which
have demonstrated to be effective in increasing retention.
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